|
|
 |
|
Viewing report
|
|
|
|
World Adult Infectious Diseases Vaccines Markets
Frost & Sullivan, Jan 2002
New Innovations, Emerging Markets Propel Vaccine Industry
Though the global vaccines market accounts for approximately two percent of
the world pharmaceutical industry, the field has witnessed considerable
changes and positive growth over the past few years. The introduction of new
delivery systems, novel and combination vaccines, and improved vaccination
rates in emerging markets are expected to significantly impact the industry.
This Frost & Sullivan analysis provides a comprehensive evaluation of the
world adult infectious diseases vaccines markets. By offering a detailed analysis
of major segments and publicly-funded programs aimed at increasing
immunization rates, this study allows firms to take advantage of key
industry trends.
Nasal Inoculation Opens Doors to Lucrative Growth Opportunities
The most promising advancement for new delivery methods for influenza
vaccines is the development of a nasal delivery vaccine. One breakthrough
product is currently awaiting final approval by the FDA.This would be the first
nasal delivery flu vaccine and should prove profitable in markets where
patients’ fear of needles is a major challenge.
Nasal delivery strategies are being employed in an effort to boost
immunization rates. By focusing on the pediatric sector, one manufacturer is
attempting to create a new market opportunities for the vaccines, states the
author of this study.
Lack of Awareness Regarding the Health Risks of Hepatitis Hinders Market
Though hepatitis B is considered a third-world disease, a significant number of
European and North American adults contract the illness each year. A large
portion of the high-risk adult population is simply not aware of the potential
health problems associated with the disease or the fact that their lifestyle may
put them at increased risk.
This is especially true for sexually active males with multiple partners. Even
among the more knowledgeable high-risk groups, increased awareness does
not always translate into a need to get vaccinated,” says the analyst.
For example, recent surveys found that the top reason these individuals had
not received the hepatitis B vaccination is they did not consider it a
medical priority.
This Frost & Sullivan research provides the most current market intelligence,
enabling industry participants to implement effective strategies for future success.
Additional Information
Market Participants
Acambis, Inc.
Antex Biologics, Inc.
Aventis S.A.
Aviron
Biochem Pharma, Inc./Shire Pharmaceuticals
Group plc
Centers for Disease Control and Prevention
Chiron Corp.
Epimmune, Inc.
GlaxoSmithKline
GlaxoSmithKline Biologicals
Hepatitis B Foundation
ImClone Systems, Inc.
Maxim Pharmaceuticals, Inc.
MedImmune, Inc.
Merck and Co.
Nabi Corp.
National Coalition for Adult Immunization
PowderJect Pharmaceuticals plc
ProdiGene, Inc.
Protein Sciences Corp.
Rhein Biotech N.V.
Customers who bought this item also bought
Infectious Diseases Vaccine Market Overview: Key Companies & Strategies - In Times of Crisis, Big Pharma turns to Vaccines
Human Vaccines - Global Strategic Business Report
World Infectious Disease Vaccine Markets
Human Vaccines - Global Market Opportunities
Human Vaccines - Global Market Opportunities
Veterinary Vaccines - A World Market Analysis
Global Vaccine Market Outlook (2007-2010)
Global Vaccine Market Forecast to 2012
Veterinary Vaccines - A World Market Analysis
China Vaccine Industry Report, 2008-2009
China Vaccine Industry Report, 2008-2009
Travelers’ Infectious Diseases: Exploiting the World of Travel Vaccines?
|
|
|
|
